Ad
Wednesday, 24 July 2019
Bristol-Myers releases mixed Opdivo lung cancer results
Bristol-Myers Squibb Co released mixed results on Wednesday from trials testing the survival benefit of its immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy, as an initial treatment for advanced lung cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment